Evidence map›Paper›PMID 42292480›Full record

ArticleFrontiers in immunology2026

Tumor immune microenvironment states inferred from TLS-associated immune-cell composition stratify prognosis in hepatocellular carcinoma.

Chihyuan Cheng, Geng Chen, Jing Zhang, Liman Qiu, Zhenli Li, Xiuqing Dong, Chenfan Lu, Qiming Wu, Xiaohui Peng, Zhixiong Cai and 1 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Chihyuan Cheng *The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
Geng Chen *The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province and Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, China.
Jing Zhang *The Fifth Hospital of Xiamen, Xiamen, China.
Liman QiuThe United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province and Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, China.
Zhenli LiThe United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province and Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, China.
Xiuqing DongThe United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province and Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, China.
Chenfan LuThe United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province and Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, China.
Qiming WuThe United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province and Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, China.
Xiaohui PengThe United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province and Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, China.
Zhixiong CaiThe United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province and Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, China.
Yongyi ZengThe First Affiliated Hospital of Fujian Medical University, Fuzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Tertiary lymphoid structures (TLS) are ectopic immune hubs in the tumor immune microenvironment (TIME) associated with prognosis and immunotherapy response, yet commonly used TLS structural descriptors show inconsistent associations with prognosis in hepatocellular carcinoma (HCC). Here, we propose a TLS-associated immune-cell composition framework that quantifies the TIME state and predicts patient outcomes. Methods: By integrating an HCC single-cell atlas with literature-curated TLS gene sets, we defined six TLS-associated immune components (TLS6). Using TLS6 as a reference, we applied BayesPrism deconvolution to infer the relative abundance of TLS6 from bulk tumor transcriptomes. Given the divergent prognostic associations across TLS6 fractions, we applied LASSO-Cox regression to derive a two-feature TLS RiskScore retaining regulatory T cells and cDC2 cells. Results: The TLS RiskScore stratified overall survival in TCGA-LIHC and ICGC LIRI-JP and was associated with response to PD-1 blockade in an independent anti-PD-1-treated HCC cohort. In multicenter FFPE tissues, a multiplex immunofluorescence (mIF) implementation quantifying TLS-localized CD4 Conclusions: Collectively, these results support a compact, translatable TLS-associated immune-cell composition framework that provides a computable TIME-state measure associated with prognosis and response to PD-1 blockade in HCC.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsTertiary Lymphoid StructuresTumor MicroenvironmentBiomarkers, TumorHumansLymphocytes, Tumor-InfiltratingPrognosisT-Lymphocytes, RegulatoryBiomarkers, Tumorhepatocellular carcinomaimmune-cell compositionimmunotherapy responsetertiary lymphoid structurestumor immune microenvironment

Identifiers

PMID42292480
PMCPMC13253696

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.